Cargando…

Application of iPS cell-derived macrophages to cancer therapy

We established a method to produce a large quantity of myeloid cells from human inducible pluripotent stem cells (iPSCs). When injected intraperitoneally into mice carrying established peritoneal tumors, iPSC-derived myeloid cells (iPS-MCs) efficiently accumulated within neoplastic lesions. The intr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Senju, Satoru, Koba, Chihiro, Haruta, Miwa, Matsunaga, Yusuke, Matsumura, Keiko, Haga, Eriko, Sasaki, Yuko, Ikeda, Tokunori, Takamatsu, Koutaro, Nishimura, Yasuharu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2014
Materias:	Author's View
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4008454/ https://www.ncbi.nlm.nih.gov/pubmed/24800175 http://dx.doi.org/10.4161/onci.27927

Ejemplares similares

Therapeutic Effect of Human iPS-Cell–Derived Myeloid Cells Expressing IFN-β against Peritoneally Disseminated Cancer in Xenograft Models
por: Koba, Chihiro, et al.
Publicado: (2013)

Suppression of Th1-Mediated Autoimmunity by Embryonic Stem Cell-Derived Dendritic Cells
por: Ikeda, Tokunori, et al.
Publicado: (2014)

Involvement of Macrophages in the Pathogenesis of Familial Amyloid Polyneuropathy and Efficacy of Human iPS Cell-Derived Macrophages in Its Treatment
por: Suenaga, Genki, et al.
Publicado: (2016)

Generation of Large Numbers of Antigen-Expressing Human Dendritic Cells Using CD14-ML Technology
por: Imamura, Yuya, et al.
Publicado: (2016)

Cancer therapy with major histocompatibility complex‐deficient and interferon β‐producing myeloid cells derived from allogeneic embryonic stem cells
por: Umemoto, Satoshi, et al.
Publicado: (2019)

Long peptide-based cancer immunotherapy targeting tumor antigen-specific CD4(+) and CD8(+) T cells
por: Tomita, Yusuke, et al.
Publicado: (2013)

IP-10/CXCL10 attracts regulatory T cells: Implication for pancreatic cancer
por: Lunardi, Serena, et al.
Publicado: (2015)

BRCA1-CtIP interaction in the repair of DNA double-strand breaks
por: Aparicio, Tomas, et al.
Publicado: (2016)

Immune‐suppressive effects of interleukin‐6 on T‐cell‐mediated anti‐tumor immunity
por: Tsukamoto, Hirotake, et al.
Publicado: (2017)

Eliminating residual iPS cells for safety in clinical application
por: Masuda, Shigeo, et al.
Publicado: (2015)

IL-6-mediated environmental conditioning of defective Th1 differentiation dampens antitumour immune responses in old age
por: Tsukamoto, Hirotake, et al.
Publicado: (2015)

Turning tolerogenic into immunogenic ileal cell death through ileal microbiota: the key to unlock the mystery of colon cancer immunoscore?
por: Roberti, Maria Paula, et al.
Publicado: (2020)

Tumor-free iPS stem cells for heart cells
por: Phillips, M Ian
Publicado: (2014)

Novel therapeutic strategies for advanced ovarian cancer by using induced pluripotent stem cell‐derived myelomonocytic cells producing interferon beta
por: Imamura, Yuko, et al.
Publicado: (2018)

Author Correction: Fingolimod-induced decrease in heart rate may predict subsequent decreasing degree of lymphocytes
por: Ikeda, Tokunori, et al.
Publicado: (2019)

Cytotoxic T lymphocytes: Sniping cancer stem cells
por: Hirohashi, Yoshihiko, et al.
Publicado: (2012)

Systemic cancer immunotherapy with Toll-like receptor 7 agonists: Timing is everything
por: Hotz, Christian, et al.
Publicado: (2012)

Chronic liver inflammation dominated by interferon-γ can prevent hepatocarcinogenesis
por: Schrader, Jörg, et al.
Publicado: (2012)

FOXO3: A master switch for regulating tolerance and immunity in dendritic cells
por: Watkins, Stephanie K., et al.
Publicado: (2012)

FIST, a sword and shield fusokine for cancer immunotherapy
por: Penafuerte, Claudia, et al.
Publicado: (2012)

Host CD73 impairs anti-tumor immunity
por: Salmi, Marko, et al.
Publicado: (2012)

Cancer immunotherapy: Benefit and harm?
por: Characiejus, Dainius
Publicado: (2012)

IL-33/ST2 axis in innate and acquired immunity to tumors
por: Jovanovic, Ivan P., et al.
Publicado: (2012)

Immunotherapy: Is it different for sarcomas?
por: Cleton-Jansen, Anne-Marie, et al.
Publicado: (2012)

What is the influence of vaccination’s routes on the regression of tumors located at mucosal sites?
por: Nardelli-Haefliger, Denise, et al.
Publicado: (2012)

New insights into the role of NK cells in cancer immunotherapy
por: Salagianni, Maria, et al.
Publicado: (2012)

STATing the importance of immune modulation by platinum chemotherapeutics
por: Hato, Stanleyson V., et al.
Publicado: (2012)

Tumor immune escape in acute myeloid leukemia: Class II-associated invariant chain peptide expression as result of deficient antigen presentation
por: van Luijn, Marvin M., et al.
Publicado: (2012)

Anti-leukemia activity of human gamma delta T cells
por: Siegers, Gabrielle M.
Publicado: (2012)

The double-edge sword effect of anti-CD73 cancer therapy
por: Stagg, John
Publicado: (2012)

Modulation of DNA repair genes induced by TLR9 agonists: A strategy to eliminate “altered” cells?
por: Sommariva, Michele, et al.
Publicado: (2012)

A novel role for granzymes in anti-tumor immunity
por: Hoves, Sabine, et al.
Publicado: (2012)

Tumor microenvironment in NSCLC suppresses NK cells function
por: Cremer, Isabelle, et al.
Publicado: (2012)

Imatinib mesylate can help to direct natural immunity toward an anti-leukemic reactivity by acting on the bone marrow microenvironment
por: Poggi, Alessandro, et al.
Publicado: (2012)

Enhanced 15-lipoxygenase activity and elevated eicosanoid production in kidney tumor microenvironment contribute to the inflammation and immune suppression
por: Kusmartsev, Sergei
Publicado: (2012)

Survivin the battle against immunosuppression
por: Manuel, Edwin R., et al.
Publicado: (2012)

Virus infections in tumors pave the way for tumor-directed DC-vaccines
por: Woller, Norman, et al.
Publicado: (2012)

Pro-survival signaling via CD27 costimulation drives effective CAR T-cell therapy
por: Song, De-Gang, et al.
Publicado: (2012)

Chemoimmunotherapy as long-term maintenance therapy for cancer
por: Egilmez, Nejat K., et al.
Publicado: (2012)

Inhibition of CXCLs/CXCR2 axis in the tumor microenvironment might be a potent therapeutics for pancreatic cancer
por: Ijichi, Hideaki
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_53p3lubsb4ps5enjfgec6icmk2